J Korean Orthop Assoc.  2016 Dec;51(6):503-508. 10.4055/jkoa.2016.51.6.503.

Synovial Sarcoma of the Extremities

• Moon JY
• Chung SH
• Oh SJ

• KMID: 2364302
• DOI: http://doi.org/10.4055/jkoa.2016.51.6.503

Abstract

PURPOSE
Synovial sarcoma is an uncommon malignant soft tissue tumor mostly prevalent in young adults. Previous studies analyzing the prognostic factors have been limited due to the inclusion of heterogenous cohorts of patients with nonextremity and recurrent tumors. The purpose of this study was to determine the independent prognostic factors for the treatment methods associated with local recurrence and metastasis of primary synovial sarcoma localized to the extremities.
MATERIALS AND METHODS
Between April 1999 and June 2014, a total of 79 patients were diagnosed with synovial sarcoma, of which 73 underwent wide excision at Kosin University Gospel Hospital and were followed-up for 60 months (24-72 months). The analyzed prognostic factors were treatment methods for local recurrence and metastasis during the postoperative follow-up period. The Cox regression model was used for multivariate analysis.
RESULTS
For local recurrence according to the treatment methods, 9 recurrences occurred in 9 surgical treatments, 8 in 20 chemotherapy added surgical treatments, 13 in 20 radiotherapy added surgical treatments, and 4 in 24 chemotherapy with radiotherapy added surgical treatments. For metastasis according to the treatment methods, 9, 5, 12, and 2 metastases occurred respectively. Chemotherapy had statistical significance in multivariate analysis (p<0.0001).
CONCLUSION
Adjuvant chemotherapy can be useful for the treatment of synovial sarcoma.

Keyword

synovial sarcoma; therapy; survival rate; local neoplasm recurrence; neoplasm metastasis

MeSH Terms

Chemotherapy, Adjuvant
Cohort Studies
Drug Therapy
Extremities*
Follow-Up Studies
Humans
Multivariate Analysis
Neoplasm Metastasis
Neoplasm Recurrence, Local
Radiotherapy
Recurrence
Sarcoma, Synovial*
Survival Rate
Young Adult

Figure

• 

  Figure 1 This graph shows the continuous disease free survival proportions of the chemotherapy and non-chemotherapy groups. By the log-rank test, the p-value was less than 0.0001.

• 

  Figure 2 This graph shows the continuous disease free survival proportions of the radiotherapy and non-radiotherapy groups. By the logrank test, the p-value was 0.07.

• 

  Figure 3 This graph shows the continuous disease free survival proportions of the local recurrence and no local recurrence groups. By the logrank test, the p-value was less than 0.0001.

• 

  Figure 4 This graph shows the continuous disease free survival proportions of the metastasis and non-metastasis groups. By the logrank test, the p-value was less than 0.0001.

Reference

1. Andrassy RJ, Okcu MF, Despa S, Raney RB. Synovial sarcoma in children: surgical lessons from a single institution and review of the literature. J Am Coll Surg. 2001; 192:305–313.

2. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999; 85:2596–2607.

3. Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma. In : DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers;1997. p. 1738–1788.

4. Bedi M, King DM, Saeed H, et al. Localized management of soft tissue sarcoma metastasis: a review of a multidisciplinary approach. Cancer Res Front. 2015; 1:162–171.

5. Song WS, Jeon DG, Park JH, et al. Long term survival of synovial sarcoma and treatment strategy. J Korean Orthop Assoc. 2004; 39:329–334.

6. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18:2087–2094.

7. Skytting B, Meis-Kindblom JM, Larsson O, et al. Synovial sarcoma: identification of favorable and unfavorable histologic types: a Scandinavian sarcoma group study of 104 cases. Acta Orthop Scand. 1999; 70:543–554.

8. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000; 18:3794–3803.

9. Trassard M, Le Doussal V, Hacène K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001; 19:525–534.

10. Thompson RC Jr, Garg A, Goswitz J, Cheng EY, Clohisy DR, Dusenbery K. Synovial sarcoma. Large size predicts poor outcome. Clin Orthop Relat Res. 2000; 373:18–24.

11. Fontanesi J, Pappo AS, Parham DM, et al. Role of irradiation in management of synovial sarcoma: St. Jude Children's Research Hospital experience. Med Pediatr Oncol. 1996; 26:264–267.

12. Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol. 2001; 37:90–96.

13. Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996; 14:1201–1208.

14. Ueda T, Yoshikawa H, Mori S, et al. Influence of local recurrence on the prognosis of soft-tissue sarcomas. J Bone Joint Surg Br. 1997; 79:553–557.